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S U M M A R Y
Background: This systematic review evaluated the incidence, etiology, and use of resources in bacterial,
non-tuberculosis community-acquired pneumonia (CAP) in immune-competent children aged <5 years.
Methods: Systematic searches (1980–2008) were performed using MEDLINE, Cochrane Library, EMBASE,
LILACS, generic, and academic Internet searches. Regional health ministries, the Pan American Health
Organization (PAHO), regional proceedings, doctoral theses, and the reference lists of included studies
were also searched, and experts were consulted. Arcsine transformations and the DerSimonian–Laird
random-effects model were used for proportion meta-analyses.
Results: The search yielded 1220 references; 60 were included in the meta-analysis, giving a total 23 854
CAP episodes with an incidence of 919/100 000 child-years in children aged <5 years. Streptococcus
pneumoniae was the most frequently isolated agent (11.08%; 95% conﬁdence interval (CI) 7.6315.08), and
pneumococcal serotype 14 was most prevalent (33.00%; 95% CI 25.9540.45). Other common agents were
Haemophilus inﬂuenzae and Mycoplasma pneumoniae. Health economics data on CAP in the region were
scarce. About one-fourth of CAP patients required hospitalization (median length of stay 11 days, range
513.5 days).
Conclusions: The burden of CAP was substantial, with S. pneumoniae, H. inﬂuenzae, and M. pneumoniae
being the most common pathogens identiﬁed. High quality primary studies on disease incidence, use of
health resources, and standardized data collection on disease burden and circulating strains are essential
to provide baseline data for the future evaluation of vaccine impact.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Pneumonia accounts for nearly four million deaths in children
worldwide each year.1 Over 90% of the estimated 1.8 million
annual deaths due to acute respiratory infections in children less
than 5 years of age occur in developing countries and are mainly
due to bacterial infections.2 Globally, it is estimated that 11–20
million of the 146 million annual childhood episodes of
community-acquired pneumonia (CAP) require hospitalization.3
Pneumonia has been observed to be more severe in developing
countries, resulting in higher mortality rates.4–6 The annual
worldwide incidence of CAP has been estimated to be between
1000 and 12 000 per 100 000 children. The rate of CAP-associated
hospitalization ranges between 22% and 50%, with an overall
fatality rate of 4% and an outpatient fatality rate of nearly 1%.7–9* Corresponding author. Tel.: +54 911 30887431; fax: +54 11 49649019.
E-mail address: angelagentile@ﬁbertel.com.ar (A. Gentile).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.09.013In Latin America and the Caribbean more than 80 000 children
aged under 5 years die every year secondary to lower respiratory
tract infections. Of these deaths, 85% are due to pneumonia and
inﬂuenza-like disease. In some countries, pneumonia and inﬂuen-
za-like disease are responsible for more than 20% of the deaths in
this age group.5,6 In the World Health Organization (WHO) Region
of the Americas, pneumonia and inﬂuenza together accounted for
11.5% of total deaths in children aged 0–4 years in 2007.10
Typical bacterial pathogens causing CAP in children under 5 years
of age include Streptococcus pneumoniae, Haemophilus inﬂuenzae,
and Mycoplasma pneumoniae. Studies on severe pneumonia with
parapneumonic effusions and life-threatening pneumonia with
lobar consolidation have also implicated these bacteria as the major
etiological agents.11,12 The relative importance of other microbial
pathogens varies over time and geographically.13 Staphylococcus
aureus is emerging as a common cause of CAP in some countries.14
Viruses account for one-fourth of CAP in children, most commonly in
those less than 5 years of age. In most studies, the etiological agent
remained unidentiﬁed in more than 50% of the cases.ses. Published by Elsevier Ltd. All rights reserved.
A. Gentile et al. / International Journal of Infectious Diseases 16 (2012) e5–e15e6The aim of this systematic review was to determine the
incidence, etiology, and resource use in bacterial CAP in
immunocompetent children aged under 5 years in Latin America
and the Caribbean.
2. Methods
2.1. Search strategy, selection criteria, screening, and data collection
We conducted a systematic search of the following electronic
databases: Cochrane CENTRAL Register and specialized register of
the Cochrane Acute Respiratory Infections Group, MEDLINE,
EMBASE, LILACS, GlobalHealth, and Pascal Biomed, from each
database’s inception date to March 2007 (Supplementary Material,
Appendix 1). An annotated search strategy for gray literature was
included to retrieve information from relevant sources, such as the
regional health ministries, the Pan American Health Organization
(PAHO), reports from hospitals, databases containing regional
proceedings or congress annals, and doctoral theses. The reference
lists of included studies were also searched, and experts and
associations related to the topic were consulted. Authors were
contacted to obtain missing or extra information when needed. We
included the control arm or baseline data of controlled trials, cohort,
case-control, cross-sectional and case-series studies, without
language restrictions, for Latin America and the Caribbean, assessing
at least one of the following CAP outcomes: prevalence, incidence,
resource use, and etiology (pathogens and serotypes). Systematic
reviews and meta-analyses with original data were also included.
Inclusion criteria were immunocompetent children under 5
years of age and chest X-ray-conﬁrmed CAP using WHO guide-
lines.15 If the age group was not differentiated in the report, the
upper age limit was extended to 12 years of age. Studies with fewer
than 20 CAP cases were excluded.
Demographic information such as ethnic origin, socioeconomic
factors, and gender were also collected.
Pairs of independent researchers screened titles and abstracts
of identiﬁed citations. They categorized the articles into one of the
following categories: potentially eligible, related reviews, related
references, and excluded. Two independent researchers assessed
the full-text of potentially eligible articles to evaluate whether
they met the inclusion criteria or not. Data were abstracted using
an electronic chart pre-piloted in 20 articles. Disagreements were
resolved by consensus in both phases.
2.2. Assessment of risk of bias and data analysis
The methodological quality of articles was evaluated by three
independent reviewers (AB, AC, DG). The risk of bias for
observational studies was assessed through the STROBE (Strength-
ening the Reporting of Observational studies in Epidemiology)16
checklist of essential items, modiﬁed according to Sanderson
et al.17 and Fowkes and Fulton.18 Brieﬂy, we used an algorithm
(Supplementary Material, Appendix 2), programmed into a
spreadsheet, to estimate a summary risk of bias considering ﬁve
criteria: methods for selecting study participants, methods for
measuring exposure and outcome variables, and methods to
control confounding, design-speciﬁc sources of bias, and statistical
methods. Disagreements were resolved by consensus.
To analyze our data, we conducted proportion meta-analyses.
We applied an arcsine transformation to stabilize the variance of
proportions (Freeman–Tukey variant of the arcsine square-root of
transformed proportions method): y = arcsin[H(r/(n + 1))] + arc-
sin[H(r/(n + 1)/(n + 1))], with a variance of 1/(n + 1), where n is the
population size.19 The pooled proportion was calculated as the
back-transformation of the weighted mean of the transformed
proportions, using inverse arcsine variance weights for the ﬁxedand random effects model. The estimates and their 95% conﬁdence
intervals (CI) were calculated using the DerSimonian–Laird
weights for the random effects model where heterogeneity
between studies was found.20 We calculated the I2 statistic as a
measure of the proportion of the overall variation in the proportion
that was attributable to between-study heterogeneity.21 StatsDir-
ect (StatsDirect Ltd, Altrincham, Cheshire, UK) and STATA 9.0
(StataCorp LP, College Station, TX, USA) packages were used for
these analyses. Incidence was expressed as the number of episodes
per 100 000 children with at least one episode of CAP per year
reported in prospective studies. To calculate pooled incidence rate
ratios we used the Comprehensive Meta-Analysis software
package, version 2.2.021 (Biostat, Englewood, NJ, USA). Stratiﬁca-
tion was done whenever possible by age, country, 2007 gross
national income (GNI), and World Bank classiﬁcation of the
country by per capita income, to explore sources of heterogeneity.
Hence, sensitivity and subgroup analyses were planned.
3. Results
The initial search yielded 1220 potential references (Figure 1),
of which 362 were retrieved as full-text for further evaluation.
Sixty references (69 studies), relating to a total 23 854 episodes of
CAP in children aged less than 5 years, were included in this
systematic review. The studies were conducted between 1980 and
2007 in Brazil (n = 17),22–38 Argentina (n = 11)11,22,39–45 (also
Ruvinsky R. Carga de neumonı´a consolidante en nin˜os menores
de 5 an˜os en la ciudad de Concordia; personal communication),
Uruguay (n = 10),22,46–54 Chile (n = 9),22,55–62 Colombia
(n = 6),22,63–67 Mexico (n = 4),22,68–70 Venezuela (n = 2),22,71 Peru
(n = 2),72,73 Panama,74 Paraguay,22 Costa Rica,75 Cuba,22 Dominican
Republic,22 Ecuador,76 and Guatemala77 (n = 1 each). The median
age of patients included in this report was 22 months. The
characteristics of the included studies are shown in Table 1.
The most frequently used study designs were case series
(n = 26) and cross-sectional (n = 21); other types were cohort,
case–control, and control arm of randomized clinical trials. The
median number of episodes of CAP per study was 146. Ten studies
described the surveillance period, with a median duration of 120
days. The risk factor ‘premature birth’ was reported in two studies
and the risk factor ‘malnutrition’ was reported in 10 studies. Other
risk factors, such as history of bronchiolitis, cardiopulmonary
disorders, tobacco smoke exposure, socio-economic status, and
day-care attendance, were seldom described in the papers
identiﬁed. The risk of bias was deemed high in 34 studies (49%),
medium in six (9%), and low in 29 (42%).
3.1. Incidence
Information on the incidence of CAP was available in eight
studies (one divided into two sub-studies) conducted between
1992 and 2005 in children aged from 1 month to 14 years across
Brazil, Chile, Argentina, and Uruguay (including Ruvinsky R. Carga
de neumonı´a consolidante en nin˜os menores de 5 an˜os en la ciudad
de Concordia (personal communication)).23,43,45,48,50,57,58 The
incidence ranged between 168 and 2450 per 100 000 child-years.
However, the incidence reported in one study from Argentina45
was much higher than that reported in the rest of the studies. The
pooled incidence was 918.81 (95% CI 488.52–1349.1) per 100 000
child-years in children under 5 years of age (Figure 2). The results
of the meta-analysis by age group are presented in Table 2.
3.2. Bacterial etiology
Thirty studies/sub-studies24–26,28–30,33–35,37,39,43,44,47,49,51–54,
56,60,62,65,67,68,71,72,74,77 (including Ruvinsky R. Carga de neumonı´a
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Figure 1. Study ﬂow diagram.
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personal communication) provided information suitable for the
random effect proportion meta-analysis of the etiological agent of
radiologically conﬁrmed CAP (Table 3). These studies were
conducted between 1980 and 2003 in Brazil, Venezuela, Mexico,
Peru, Uruguay, Colombia, and Chile, in children aged from 1 month
to 14 years. The diagnosis was made predominantly by blood and/or
pleural ﬂuid cultures.
S. pneumoniae was the predominant etiological agent in all
countries, with a pooled prevalence of 11.08% in 29 studies (95% CI
7.63–15.08). Other frequently reported microorganisms were H.
inﬂuenzae (pooled prevalence 3.64%, 95% CI 1.62–6.42 in 12
studies) and M. pneumoniae (pooled prevalence 3.56%, 95% CI 0.99–
7.64 in six studies). Bacterial co-infection was reported in 3.88%
(95% CI 0.72–9.40) of cases. Studies that used precision diagnostic
techniques, such as dot enzyme-linked immunosorbent assay (dot-
ELISA) and C-reactive protein (CRP), also identiﬁed S. pneumoniae
as the most frequent etiological agent of pneumonia.33,34 In most
studies (18 studies; 60.06%, 95% CI 44.62–74.54), the etiological
agent remained unidentiﬁed.
Methods for the diagnosis of M. pneumoniae and Chlamydia spp
pneumonia were not consistently reported. For the identiﬁcation
of M. pneumoniae, serology tests used in the studies included the
agglutination method,29 immunoﬂuorescence, and PCR.42,68,74
Isolation in cell culture was used in two studies. For Chlamydia
pneumoniae serological methods included micro-immunoﬂuores-
cence41,60 and immunoﬂuorescence.44,49 Culture in cells with PCR
was done in one study.74
The rate of infection by speciﬁc organisms varied according to
the income level of the country and patient age; however more
data were available from middle-income countries than from low-
income countries. In low-income countries, H. inﬂuenzae, S. aureus,
and S. pneumoniae were the most frequently reported micro-organisms (12.04%, 95% CI 6.17–19.52; 10.72%, 95% CI 3.30–21.70;
and 8.94%, 95% CI 2.9–17.85, respectively). The middle-income
countries had a pooled prevalence of S. pneumoniae of 12.00% (95%
CI 7.64–17.19), followed by M. pneumoniae 3.88% (95% CI 0.82–
9.07) and H. inﬂuenzae 2.68% (95% CI 1.00–5.14). The etiological
agent could not be identiﬁed in up to 64% of cases due to the
absence of microbial growth. The etiology of CAP was evaluated in
two age groups: 0–23 months and 24–60 months. The pooled
prevalence of S. pneumoniae was 9.69% (95% CI 4.41–16.74) in the
ﬁrst age group and 17.32% (95% CI 2.49–72.33) in the second age
group. The pooled prevalence of H. inﬂuenzae was 11.21% (95% CI
4.63–20.18) in those aged 0–23 months and 12.12% (95% CI 2.40–
27.82) in those aged 24–60 months. Results of the meta-analysis of
etiology by subgroups of age and World Bank income deﬁnition are
presented in Table 4.
3.3. Pneumococcal serotypes
Ten papers presented pertinent data on the various serotypes of
S. pneumoniae as etiological agents of CAP in children aged less
than 5 years (including Ruvinsky R. Carga de neumonı´a con-
solidante en nin˜os menores de 5 an˜os en la ciudad de Concordia;
personal communication).22,27,31,35,43–46,52 Across studies, sero-
type 14 was the most common, varying from 31% to 55% of
pneumococcal pneumonia cases, and showing a pooled prevalence
of 33.00% (95% CI 25.95–40.45). Other less frequently associated
serotypes were serotype 1 (10.96%; 95% CI 9.17–12.88) and
serotype 5 (10.84%; 95% CI 7.3–14.99) (see Table 5). Non-typed
serotypes had a prevalence of 12.88% (95% CI 0.62–37.12).
Pneumococcal serotype 14 was the most prevalent in all age
categories (0–23 months: 51.1% (95% CI 45.17–57.02) and 24–60
months: 30.82% (95% CI 23.97–38.13)), as well as by World Bank
income classiﬁcation of the region (low-income countries: 36.99%
Table 1
Characteristics of the populations included in the meta-analysis, listed by country
Country
(number of studies)
Study Population
studied
Median agea
(months)
Age range
(months)
Pneumonias
(n)
Males (n) Population
characteristics
Duration
(months)
Complexity
of health care
Argentina (11) Avila et al., 199039 1–60 1230 53 N/A
Bakir 200140 22 0–60 188 118 <24 months (53%); malnutrition (12%);
previous bronchiolitis (22%)
12 Medium-high level
Carballal et al., 199241 5/6 1–18 86 12 Medium-high level
Ferrero 200042 24 0–119 197 110 36 Medium-high level
Gentile et al., 200843 27 209 0–59 611 337 Ambulatory (40%) 36 Medium-high level
Rowensztein et al., 200711 384 4/8 36 3 N/A
Ruvinsky, Concordia 2008b 16 148 0–59 332 Ambulatory (42%), undernourished
(3%); antibiotic use during the previous
3 months (29%)
24 Medium-high level
Ruvinsky, Parana´ 2008b 28 739 0–59 390 24 Medium-high level
Sequeira et al., 199744 2–60 237 Malnutrition (15%); not breastfed (10%) 23 Low level
SIREVA II, Argentina22,c 0–60 519 72 Medium-high level
Tregnaghi et al., 200645 86 211 2–23 82 36 N/A
Brazil (17) Andrade et al., 200423 95 936 724 12 N/A
Carvalho et al., 199224 1–144 45 All with pleural effusion; previous
bronchiolitis (18%); cardiopulmonary
disorders (16%)
12 N/A
Cirino et al., 200425 115 57 120 N/A
Freitas et al., 200626 3–60 100 N/A
Kiertsman et al., 200327 3–144 50 36 Low level
Kunyoshi et al., 200628 1–121 394 Caucasian/other white 24 Medium-high level
Nacul et al., 200529 19 6–59 472 12 N/A
Nascimento-Carvalho et al., 200131 23 24–71 18 25 N/A
Nascimento-Carvalho et al., 200230 24/35 0–60 2246 1863 Afro-American 25 Medium-high level
Pinto et al., 200432 350 22 3–59 154 86 Afro-American; all hospitalized 10 Medium-high level
Requejo et al., 199434 500 0–144 442 12 Medium-high level
Requejo et al., 200333 265 12 N/A
Rey et al., 200235 2–59 482 269 Afro-American; cardiopulmonary
disorders (15%)
9 Medium-high level
Riccetto et al., 200336 3375 1–3 509 274 12 Medium-high level
Rodriguez Pereira et al., 199137 116 82 Afro-American;<12months (54%); 12–
35 months (29%); 36–59 months (14%);
60 months (10%)
5 Medium-high level
SIREVA II, Brazil22,c 0–60 528 72 Medium-high level
Victora et al., 199438 0–23 510 247 Malnutrition (9%); previous
bronchiolitis (38%); exposure to
tobacco smoke (65%); day-care center
(14%)
12 Medium-high level
Chile (9) Cha´vez and Rauch 199955 109 67 72 Medium-high level
Garcı´a et al., 198856 1–71 27 12 Medium-high level
Lagos 200757 29 524 1–35 534 24 Medium-high level
Levine et al., 199958 21 420 4–23 157 29 Medium-high level
Lopez et al., 199659 437 0–24 210 24 Low level
Martinez Tagle et al., 200060 61 1–168 112 24 Low level
Mora et al., 200061 0–72 273 131 12 Low level
Paz et al., 200162 36 24–71 108 90 Caucasian/other white; malnutrition
(9%)
186 Medium-high level
SIREVA II, Chile22,c 0–60 268 72 Medium-high level
Colombia (6) Alvis Guzman et al., 200563 0–24 128 74 Sample of 11.6% of all admissions;
prematurity (9%); malnutrition (10%)
18 Medium-high level
Alvis Guzman et al., 200664 2–23 64 17 Medium-high level
Cespedes Londono et al., 200465 >1 202 115 23 Medium-high level
Escobar et al., 198966 24 1–179 410 29 48 Medium-high level
Levy et al., 198867 0–6 55 44 All with pleural effusion 72 N/A
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Table 1 (Continued )
Country
(number of studies)
Study Population
studied
Median agea
(months)
Age range
(months)
Pneumonias
(n)
Males (n) Population
characteristics
Duration
(months)
Complexity
of health care
SIREVA II, Colombia22,c 0–60 253 72 Medium-high level
Costa Rica Farrow and Mahony 198875 2 39 24 3 N/A
Cuba SIREVA II Cuba22,c 0–60 215 72 Medium-high level
Dominican Republic SIREVA II, Dominican Republic22,c 0–60 277 72 Medium-high level
Ecuador Rodriguez et al., 200576 287 166 Cardiopulmonary disorders (28.5%) 25 Medium-high level
Guatemala Asturias et al., 200377 8 725 425 <6 months (37%); 6–12 months (28%) 28 Medium-high level
International Hortal et al., 200081 1–59 1409 69 N/A
Mexico (4) Garcia Ramos et al., 199168 1–71 123 36 Low level
Gutie´rrez Trujillo et al., 198969 0–84 31 Vigilance period 7 days 12 Low level
Pe´rez et al., 199570 252 12 4–23 142 119 Caucasian/other white 12 Medium-high level
SIREVA II, Mexico22,c 0–60 363 72 Medium-high level
Panama Sa´ez-Llorens et al., 199874 6–96 157 22 N/A
Paraguay SIREVA II, Paraguay22,c 0–60 225 72 Medium-high level
Peru (2) Grupo Multifuncional de Neumonı´as 200372 1–59 1210 14 N/A
Gudiel Hermoza 199473 2–60 238 36 Low level
Uruguay (10) Camou et al., 200346 281 605 0–60 330 12 N/A
Ferrari et al., 200247 307 4 Low level
Hortal et al., 199449 17 1–60 541 290 42 N/A
Hortal et al., 200748 18 659 0–59 2034 36 Medium-high level
Iraola Ferro et al., 200550 45 103 96 60–168 362 Malnutrition (4%); cardiopulmonary
disorders (17%)
36 N/A
Mogdasy Seluja et al., 199451 1–60 473 N/A
Pirez et al., 200153 1–60 1163 650 All hospitalized; <1 month (1%); 1–11
months (29%); <60 months 50%
12 N/A
Pı´rez Garcı´a et al., 200352 5370 1–168 697 395 Caucasian/other white; malnutrition
(17%); cardiopulmonary disorders (8%)
12 Medium-high level
Sarachaga 200154 2–10 1163 650 All hospitalized 12 N/A
SIREVA II, Uruguay22,c 0–60 426 72 Medium-high level
Venezuela (2) Centritto et al., 199071 48 9–108 33 23 All with pleural effusion 15 N/A
SIREVA II, Venezuela22,c 0–60 187 72 Medium-high level
N/A, not available.
a Mean only if the median was not reported.
b Ruvinsky R. Carga de neumonı´a consolidante en nin˜os menores de 5 an˜os en la ciudad de Concordia (personal communication).
c The SIREVA II report is presented by country.
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Figure 2. Forest plot for the meta-analysis of CAP incidence per 100 000 child-years.
aRuvinsky R. Carga de neumonı´a consolidante en nin˜os menores de 5 an˜os en la ciudad de Concordia (personal communication; 2008).
Table 3
Prevalence of pathogens in the analyzed specimens
Etiology Studies (n) Prevalence (95% CI)
A. Gentile et al. / International Journal of Infectious Diseases 16 (2012) e5–e15e10(95% CI 23.65–51.42) and middle-income countries: 30.77% (95%
CI 21.76–40.58)). Serotypes 1 (10.69%; 95% CI 9.17–12.88) and 5
(10.84%; 95% CI 7.30–14.99) were the following most prevalent in
children under 5 years of age (Figure 3). Results of the meta-
analysis by subgroups of age and World Bank classiﬁcation are
presented in Table 6.
3.4. Resource use
Scarce information is available in the region regarding resource
use for CAP in children. This review found evidence in 25 published
articles presenting data from Brazil, Argentina, Uruguay, Chile,
Colombia, Venezuela, Mexico, and Ecua-
dor.11,24,28,31,32,36,44,47,49,50,52–55,57,62–65,69–71,73,76,78 These studies,
conducted between 1986 and 2003, showed that 23–29.7% of CAP
cases required hospitalization and that 3.2% required intensive
care unit stays.54 The median length of stay for patients admitted
to general care was 11 days (range 5–13.5 days). For those patients
requiring surgery, for example to resolve abscesses or pleural
involvement, the average stay was longer. Two reports showed
that 47.7% of patients received antibiotics prior to hospitalization,
and as many as 90% received antibiotics during hospitaliza-
tion.50,55 Direct costs associated with CAP include the costs related
to hospital stay, pharmacological treatment, thoracic drainage,
transfusions, oxygen therapy, and laboratory tests (blood micro-
biological analysis, serology tests, biochemistry, microscopic
analysis, etc). Indirect costs have also been identiﬁed and include
loss of productivity during hospitalization or health care visits and
the loss of days of work for parents or primary caregivers
(designated persons taking care of the children for the majority ofTable 2
Meta-analysis of CAP incidence per 100 000 child-years by age group
Age group Studies (n) Incidence (95% CI)
0–23 monthsa 7 1412.01 (704.97–2119.05)
0–11 months 4 1587.21 (1303.18–1871.25)
12–23 months 4 964.29 (778.19–1150.39)
24–60 months 5 538.92 (346.39–731.44)
All (0–60 months) 9 918.81 (488.52–1349.1)
CAP, community-acquired pneumonia; CI, conﬁdence interval.
a Three studies reported the data aggregated from 0 to 23 months.time). The impact of CAP on these direct and indirect costs was
profound.63,64 Studies from Colombia and Argentina have reported
that the estimated direct cost in these countries could range from
US$ 248.3 to US$ 315.1 (purchasing power parity (PPP), 2009) and
US$ 562.9 to US$ 1112.7 (PPP, 2009), respectively. The average
indirect cost ranged from US$ 67.6 to US$ 133.6 (PPP, 2009).11,64 A
meta-analysis could not be conducted for resource use due to the
heterogeneity of available data.
4. Discussion
This review aimed to present a comprehensive summary of all
relevant published and unpublished data regarding CAP in children
aged less than 5 years in Latin America and the Caribbean. Using
studies that measured incidence directly, we found a point
incidence of 919 CAP cases per 100 000 children aged under 5
years, with the incidence being higher in children aged under 2
years (1412 per 100 000) than in those aged 26 years (539 per
100 000). About one-fourth of CAP patients required hospitaliza-
tion and the median length of stay was 11 days.
Previous CAP studies in Latin America and the Caribbean have
demonstrated a large variation in incidence, likely due to
differences in methodology and data collection. A 2006 United
Nations Children’s Fund (UNICEF) publication reported an
estimated incidence of 22 000 cases of pneumonia per 100 000Streptococcus pneumoniae 29 11.08 (7.63–15.08)
Haemophilus inﬂuenzae 12 3.64 (1.62–6.42)
Mycoplasma pneumoniae 6 3.56 (0.99–7.64)
Staphylococcus aureus 21 3.44 (2.08–5.11)
Haemophilus inﬂuenzae type b 11 3.08 (1.21–5.79)
Chlamydia trachomatis 5 2.97 (0.74–6.60)
Chlamydia pneumoniae 3 2.6 (0.22–7.46)
Streptococcus pyogenes 8 1.54 (0.49–3.15)
Mycoplasma hominis 1 0.81 (0. 02–4.45)
Other bacteria 16 4.38 (2.18–7.30)
Bacterial co-infection 4 3.88 (0.72–9.40)
No growth 18 60.06 (44.62–74.54)
CI, conﬁdence interval.
Table 4
Prevalence of pathogens by age and country World Bank classiﬁcation
Microorganism Subgroups Studies (n) Prevalence (95% CI)
No growth Age 0–23 months - -
24–60 months - -
WBC LIC 3 45.47 (4.49–91.02)
MIC 14 64.00 (79 49.48–78.69)
Streptococcus pneumoniae Age 0–23 months 4 9.69 (4.41–16.74)
24–60 months 2 17.32 (2.49–72.33)
WBC LIC 5 8.94 (2.9–17.85)
MIC 22 12.00 (7.64–17.19)
Haemophilus inﬂuenzae type b Age 0–23 months - -
24–60 months - -
WBC LIC 2 1.4 (0.01–5.98)
MIC 9 3.58 (1.20–7.16)
Haemophilus inﬂuenzae Age 0–23 months 2 11.21 (4.63–20.18)
24–60 months 2 12.12 (2.40–27.82)
WBC LIC 2 12.04 (6.17–19.52)
MIC 10 2.68 (1.00–5.14)
Mycoplasma pneumoniae Age 0–23 months - -
24–60 months - -
WBC LIC - -
MIC 5 3.88 (0.82–9.07)
Chlamydia pneumoniae Age 0–23 months - -
24–60 months - -
WBC LIC - -
MIC 3 2.60 (0.22–7.46)
Chlamydia trachomatis Age 0–23 months 2 6.60 (0.63–31.76)
24–60 months - -
WBC LIC - -
MIC 2 1.54 (0.27–3.85)
Staphylococcus aureus Age 0–23 months 2 32.22 (21.26–44.28)
24–60 months 2 20.57 (7.15–38.64)
WBC LIC 4 10.72 (3.30–21.70)
MIC 17 2.38 (1.32–3.74)
Streptococcus pyogenes Age 0–23 months - -
24–60 months - -
WBC LIC - -
MIC 7 1.77 (0.44–3.99)
Other bacteria Age 0–23 months 2 35.73 (0.35–94.8)
24–60 months 2 19.34 (6.38–37.15)
WBC LIC 3 2.48 (0.59–5.62)
MIC 13 4.88 (2.16–8.61)
Bacterial co-infection Age 0–23 months - -
24–60 months - -
WBC LIC - -
MIC 4 3.88 (0.72–9.4)
CI, conﬁdence interval; WBC, World Bank classiﬁcation; LIC, low-income country; MIC, middle-income country.
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year.79 Constenla et al. showed a median incidence of clinical
pneumonia of 4363 episodes per 100 000 children less than 2 years
of age, and a median incidence of radiologically and consolidation-Table 5
Prevalence of pneumococcal serotypes in the analyzed specimens
Serotype Studies/sub-studies (n) Prevalence (95% CI)
14 20 33.00 (25.95–40.45)
NT 3 12.88 (0.62–37.12)
1 17 10.96 (9.17–12.88)
5 18 10.84 (7.3–14.99)
6B 18 7.44 (5.69–9.40)
15C 2 5.19 (0.00–19. 54)
19A 15 4.67 (3.13–6.49)
6A 14 4.4 (2.06–7.56)
9V 14 3.62 (3.04–4.23)
7F 16 3.48 (2.21–5.02)
3 14 3.26 (2.21–4.51)
23F 14 3.1 (1.74–4.85)
19F 12 2.85 (1.14–5.31)
12F 2 2.58 (0.38–6.65)
18C 12 1.75 (0.67–3.32)
4 13 1.04 (0.74–1.39)
Other 16 9.39 (6.57–12.65)
CI, conﬁdence interval; NT, non-typed.conﬁrmed pneumonia of 2132 per 100 000 in the same age group.
For children under 5 years of age, the median incidence of clinical
pneumonia was 3059 per 100 000.80 A total of 327 000 pneumonia
cases (clinical and chest X-ray positive) have been estimated to
occur annually in Latin America and the Caribbean.80
In 2000, Rudan et al.3 calculated and published the ﬁrst global
estimate of the incidence of clinical pneumonia in children aged
under 5 years based on data from 28 community-based
longitudinal studies from developing countries published be-
tween 1969 and 1999. The estimated median incidence for
developing countries was 28 000 episodes per 100 000 child-
years, corresponding to 146.5 million (interquartile range 107.3–
371.6) new cases of clinical pneumonia annually.3 Of the 28
studies, only ﬁve were conducted in Latin America, therefore the
estimation of the incidence of CAP was based only on these ﬁve
studies. Our review used data compiled from studies that
measured incidence directly. This methodology is more likely
to reﬂect the true incidence than prior studies, highlighting the
importance of distinguishing the source and methods used in data
collection.
Given the burden of CAP in children under 5 years of age,
deﬁning causative agents and their antibiotic susceptibility is of
paramount importance. In 1993, PAHO developed the Regional
System for the Development of Vaccines (SIREVA) program, a
Figure 3. Prevalence of pneumococcal serotypes as etiological agents of radiologically conﬁrmed CAP (each percentage comes from a separate meta-analysis and the line
represents the upper limit 95% conﬁdence interval).
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six Latin American countries.22,81
In the current systematic review, S. pneumoniae was deter-
mined to be the dominant etiological agent of CAP in the region,
followed by H. inﬂuenzae and M. pneumoniae. Pneumococcal
serotype 14 was the most prevalent strain, followed by serotypes 1
and 5. The prevalence of serotype 14 was clearly highest in children
under 2 years of age. Serotypes 1 and 5 were more prevalent in
children over 2 years of age (Table 6). These serotypes are not
usually carried in the nasopharynx, but they cause invasive
disease, with serotype 5 often being involved in meningitis cases
and serotype 1 in CAP cases with pleural effusion.45,82 The new
pneumococcal conjugate vaccines (PCVs) – the 10- and 13-valent
ones – cover these serotypes, and according to epidemiological
data these will be of value in our countries. All included studies
that assessed H. inﬂuenzae as a possible etiology had recruited
patients before the year 2000. Therefore, most of these infections
were most likely due to H. inﬂuenzae type b (Hib), since most Latin
American countries had not included the Hib vaccine into universal
mass vaccination before the year 2000. This was most noticeable in
the 0–23 months age group, where H. inﬂuenzae ranked ﬁrst.
However, the importance of non-typeable b H. inﬂuenzae in CAP
disease is yet to be well deﬁned.
The high incidence and mortality from CAP make it imperative
that the cost burden be better understood. Hospitalization rates
are an important contributor to the direct cost of CAP.83 In an
unpublished cost-effectiveness model developed by the Instituto
de Efectividad Clı´nica y Sanitaria (IECS), ofﬁcial hospitalization
rates were calculated from each country’s hospital discharge
databases for the public sector (Divisio´n de Planiﬁcacio´n Sanitaria,
Departamento de Estadı´sticas e Informacio´n de Salud, Ministerio
de Salud de Chile; personal communication).84,85 They were
coupled with population projections for each age range, and
corrected by the information coverage level (completeness of
reporting of systems). Consistent with the ﬁndings of the current
systematic review, hospitalization rates were persistently higher
in children younger than 1 year (ranging from 640 to 2715 per100 000) than for children aged 1–5 years (ranging from 273 to
1563 per 100 000). A recent publication showed a similar median
annual hospitalization rate of 1174/100 000 children for all-cause
radiologically conﬁrmed pneumonia in children under 5 years
old.86
Treatment and length of hospitalization also contribute to the
cost burden of CAP, and these are considerable in several countries
of Latin America and the Caribbean.11,63,64,87 Constenla et al.
estimated the costs of pneumococcal disease in Brazil, Chile, and
Uruguay, and how these costs varied among different patient
groups from the health care perspective.88 Treatment costs of
pneumococcal pneumonia ranged from US$ 372 per child to US$
3483 per child. The main source of this cost discrepancy was the
level of care provided and the country in which costs were
incurred. Data from the Brazilian Ministry of Health for the years
1999–2007 report an average length of stay for pneumonia of 5.4
days,89 with marked regional differences. The average cost per
admission reported by the Brazilian Ministry of Health ranged
from US$ 97.3 in 1999 to US$ 135.3 in 2003.89 One contributor to
the high cost of hospitalization is inappropriate initial empiric
management of CAP through use of antibiotics, which leads to
higher health care costs.
Vaccines have been proven to reduce morbidity and mortality,
and therefore to reduce the cost burden, of CAP. In developing
countries with a high burden of pneumonia, vaccine studies have
proven that 15–30% of radiological pneumonia cases, and probably
the same proportion of pneumonia deaths, are due to Hib.90 In the
USA there has been a documented increase in non-vaccine
serotypes since the introduction of the heptavalent conjugate
vaccine, suggesting that implementation of broader spectrum
vaccines may be necessary.91,92 Pneumococcal efﬁcacy trials in
developing countries have shown that the 9-valent pneumococcal
conjugate vaccine can prevent 20–35% of radiological pneumonia
cases and probably a similar proportion of pneumonia deaths.93–95
Although the newer pneumococcal vaccines covering 10–13
serotypes will likely extend the protection considerably,90,96 the
public health beneﬁt of vaccines in preventing pneumonia would
Table 6
Prevalence of pneumococcal serotypes by age and country World Bank classiﬁcation
Serotype Subgroups Studies (n) Prevalence (95% CI)
14 Age 0–23 months 2 51.1 (45.17–57.02)
24–60 months 2 30.82 (23.97–38.13)
WBC LIC 5 36.99 (23.65–51.42)
MIC 13 30.77 (21.76–40.58)
18C Age 0–23 months 2 0.61 (0.03–1.87)
24–60 months - -
WBC LIC 5 3.13 (0.29–8.87)
MIC 6 1.10 (0.57–1.81)
1 Age 0–23 months 2 5.10 (2.81–8.02)
24–60 months 2 16.52 (4.12–34.95)
WBC LIC 5 9.96 (8.36–11.68)
MIC 10 12.09 (9.41–15.06)
6B Age 0–23 months 2 6.96 (1.57–15.75)
24–60 months 2 7.06 (0.11–29.24)
WBC LIC 5 9.15 (6.91–11.67)
MIC 11 5.92 (3.91–8.32)
5 Age 0–23 months 2 10.93 (7.50–14.90)
24–60 months 2 18.85 (13.22–25.22)
WBC LIC 5 6.87 (2. 46–13.28)
MIC 11 14.04 (8.68–20.43)
9V Age 0–23 months 2 3.65 (1.75–6.2)
24–60 months - -
WBC LIC 5 3.27 (1.89–5.00)
MIC 8 3.72 (3.01–4.50)
7F Age 0–23 months 2 3.65 (1.75–6.20)
24–60 months - -
WBC LIC 5 2.39 (0.59–5.36)
MIC 10 4.22 (2. 52–6.33)
19F Age 0–23 months 2 0.97 (0.12–5.32)
24–60 months - -
WBC LIC 5 2.47 (0.20–7.18)
MIC 6 3.17 (0.81–7.02)
6A Age 0–23 months - -
24–60 months - -
WBC LIC 5 3.43 (2.08–5.09)
MIC 7 5.29 (1.22–11.99)
23F Age 0–23 months 2 1.44 (0.37–3.19)
24–60 months 2 3.57 (1.27–6.97)
WBC LIC 5 3.35 (1.95–5.12)
MIC 7 3.02 (0.97–6.15)
4 Age 0–23 months 2 0.43 (0.00–1.56)
24–60 months - -
WBC LIC 5 1.37 (0.80–2.09)
MIC 7 0.95 (0.43–1.67)
19A Age 0–23 months - -
24–60 months - -
WBC LIC 5 3.29 (1.65–5.45)
MIC 8 5.83 (3.48–8.74)
3 Age 0–23 months 2 4.45 (0.46–12.20)
24–60 months - -
WBC LIC 5 3.38 (1.44–6.09)
MIC 8 3.36 (2.05–4.99)
CI, conﬁdence interval; WBC, World Bank classiﬁcation; LIC, low-income country;
MIC, middle-income country.
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good sensitivity. Exploratory studies indicate that the sensitivity of
‘radiologically conﬁrmed pneumonia’ underestimates the burden
of pneumococcal pneumonia prevented by the PCV by as much as
63%.97 Therefore, improving the efﬁciency of sentinel units in
reference hospitals in gathering information on radiologically
conﬁrmed and unconﬁrmed cases is needed.
It would be useful to compare outcomes in the pre- and post-
vaccination era, but as of March 2007, very few countries (Costa Rica,
Mexico, and Uruguay) in Latin America and the Caribbean had
adopted the PCV into their national immunization calendar. Perhaps
in the near future these comparisons will be possible. Most studies
showed variations in the reported incidence. Yet, our ﬁndings may
represent the best possible estimations obtainable from the
literature for Latin America and the Caribbean for the years
considered. They are valuable for the decision-making processand may also serve as inputs for future health economic evaluations
and several other types of study, such as time trend analyses and
surveillance initiatives.
Our systematic review was limited by the paucity of studies of
good methodological quality from the region, since most informa-
tion was cross-sectional, often coming from isolated hospitals or
non-representative samples. Proper systematic surveillance for CAP
remains a difﬁcult undertaking for regional governments due to
under-reporting of ambulatory cases. For hospitalized CAP patients,
the etiology is frequently unknown because of the lack of laboratory
conﬁrmation. We included different studies in every meta-analysis
for each pathogen and serotype in order to include all the available
information, which explains why the cumulative point estimates are
not exactly 100%. For subgroups of age and income deﬁnitions
according to the World Bank classiﬁcation, conﬁdence intervals
overlap and no ﬁrm conclusions could be drawn. Finally, a meta-
analysis could not be conducted for health resource use because data
were not available from most of the Latin American and Caribbean
countries.
In conclusion, CAP among the children of Latin America and the
Caribbean remains a disease of high morbidity and mortality. The
main bacterial causes are S. pneumoniae and H. inﬂuenzae, but
estimates of their relative importance vary in different settings and
subgroups. Pooled incidence estimates presented in this system-
atic review will contribute to a better understanding of the burden
of CAP in children under 5 years of age in Latin America and the
Caribbean, and will be useful for decision-makers with regards to
vaccination policies. SIREVA was very important for strengthening
the region’s laboratory-based surveillance, however systematic
and broader efforts began in 2000, and the majority of the studies
identiﬁed were carried out prior to this date. It is important to
strengthen and support surveillance systems to document the
evolving epidemiological patterns of CAP due to geographical
differences across countries, differences in age group distribution,
and variation in serotype and pathogen prevalence in the region.
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